Trial
NCT03711162
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Lakefront Biotherapeutics NV
Collaborators
—
Condition
Idiopathic Pulmonary Fibrosis
Intervention
GLPG1690
Why stopped
The benefit-risk profile no longer supports continuing the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-29